• Xiao-jing Gu
  • Bei Cao
  • Hui-fang Shang


Nocturia is a used to define the condition in which the individual has to wake at night one or more times to void, which was frequently complained by more than 60% patients with PD. The pathophysiological mechanisms causing nocturia in patients with PD remains poorly understood. Decreased bladder capacity, nocturnal polyuria, circadian rhythm disturbances, some living habits, and comorbidities are thought to be contributing to nocturia in patients with PD. For the diagnosis of nocturia in PD, detailed medical history and urinary diary are needed. More importantly, ultrasonography and urodynamics also help. Nocturia in PD patients has detrimental impact on patients’ quality of life; therefore, multiple disciplinary managements are needed to ameliorate symptoms. These include pharmacological management, lifestyle change, and urology referral when necessary. Medication for treating nocturia in PD includes dopamine agonists, antimuscarinic agents, desmopressin, and melatonin. Moreover, intermittent catheterization, botulinum toxin injection, deep brain stimulation, and neuromodulation are also efficient for the management of nocturia in PD.


Nocturia Reduced bladder capacity Nocturnal polyuria Circadian rhythm disturbances Medication Intermittent catheterization Botulinum toxin injection Deep brain stimulation Neuromodulation 


  1. 1.
    Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease : a review. Parkinsonism Relat Disord. 2009;15(2):81–7.CrossRefGoogle Scholar
  2. 2.
    Madan A, Ray S, Burdick D, Agarwal P. Management of lower urinary tract symptoms in Parkinson’s disease in the neurology clinic. Int J Neurosci. 2017;127(12):1136–49.CrossRefGoogle Scholar
  3. 3.
    Van KP, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia : report from the Standardisation Sub-committee of the International Continence Society. BMJ Int. 2002;183(2):179–83.Google Scholar
  4. 4.
    Rana AQ, Vaid H, Akhter MR, Awan NY, Fattah A, Cader MH, et al. Prevalence of nocturia in Parkinson’s disease patients from various ethnicities. Neurol Res. 2014;36(3):234–8.CrossRefGoogle Scholar
  5. 5.
    Rana AQ, Paul DA, Qureshi AM, Ghazi A, Alenezi S, Rana MA, et al. Association between nocturia and anxiety in Parkinson’s disease. Neurol Res. 2015;37(7):563–7.CrossRefGoogle Scholar
  6. 6.
    Yeo L, Singh R, Gundeti M. Urinary tract dysfunction in Parkinson’s disease : a review. Int Urol Nephrol. 2012;44(2):415–24.CrossRefGoogle Scholar
  7. 7.
    Sakakibara R, Panicker J, Finazzi-agro E, Iacovelli V, Bruschini H. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.CrossRefGoogle Scholar
  8. 8.
    Batla A, Phe V, De ML, Panicker JN. Nocturia in Parkinson’s disease : why does it occur and how to manage ? Mov Disord Clin Pract. 2016;3(5):443–51.CrossRefGoogle Scholar
  9. 9.
    Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, et al. Bladder function of patients with Parkinson’s disease. Int J Urol. 2014;21(7):638–46.CrossRefGoogle Scholar
  10. 10.
    Easton A, Ph D, Meerlo P, Ph D, Bergmann B, Ph D, et al. The suprachiasmatic nucleus regulates sleep timing and amount in mice. Sleep. 2004;27(7):1307–18.CrossRefGoogle Scholar
  11. 11.
    Kudo T, Loh DH, Truong D, Wu Y, Colwell CS. Circadian dysfunction in a mouse model of Parkinson’s disease. Exp Neurol. 2011;232(1):66–75.CrossRefGoogle Scholar
  12. 12.
    Buser N, Ivic S, Kessler TM, Kessels AGH, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder : network meta-analyses. Eur Urol. 2012;62(6):1040–60.CrossRefGoogle Scholar
  13. 13.
    Matsuta Y, Yusup A, Tanase K, Ishida H, Akino H. Melatonin increases bladder capacity via GABAergic system and decreases urine volume in rats. J Urol. 2010;184(1):386–91.CrossRefGoogle Scholar
  14. 14.
    Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient : clinical assessment and management. Lancet Neurol. 2015;14(7):720–32.CrossRefGoogle Scholar
  15. 15.
    Kuno S, Mizuta E, Yamasaki S, Araki I. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004;10(3):181–7.CrossRefGoogle Scholar
  16. 16.
    Rosa-grilo M, Qamar MA, Chaudhuri KR. Rotigotine transdermal patch and sleep in Parkinson’s disease : where are we now? NPJ Parkinson’s Dis. 2017;3:28.Google Scholar
  17. 17.
    Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord. 1995;10(3):337–40.CrossRefGoogle Scholar
  18. 18.
    Marinkovic SP, Gillen LM, Stanton SL. Managing nocturia. BMJ. 2004;328(7447):1063–6.CrossRefGoogle Scholar
  19. 19.
    Giannantoni A, Rossi A, Mearini E, Del ZM, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–7.CrossRefGoogle Scholar
  20. 20.
    Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960–4.CrossRefGoogle Scholar
  21. 21.
    Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinson’s disease. Neurourol Urodyn. 2012;31(8):1279–83.CrossRefGoogle Scholar
  22. 22.
    Witte LP, Odekerken VJJ, Boel JA, Schuurman PR, Gerbrandy-Schreuders LC, de Bie RMA, et al. Does deep brain stimulation improve lower urinary tract symptoms in Parkinson’s disease? Neurourol Urodyn. 2018;37(1):354–9.CrossRefGoogle Scholar
  23. 23.
    Booth J, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome : a systematic review. Neurourol Urodyn. 2018;37(2):528–41.CrossRefGoogle Scholar
  24. 24.
    Carolina M, Carlos P, Levi A, Martins R, Anelyssa C, Lucio A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Cont Nurs. 2015;42(1):94–9.CrossRefGoogle Scholar
  25. 25.
    Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(1):96.e1–5.Google Scholar
  26. 26.
    Griffiths DJ, Mccracken PN, Harrison GM, Ann Gormley E. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn. 1993;12(1):1–7.CrossRefGoogle Scholar
  27. 27.
    Weiss JP, Blaivas JG. Nocturia. J Urol. 2000;163(1):5–12.CrossRefGoogle Scholar
  28. 28.
    Batla A, Tayim N, Pakzad M, Panicker JN. Treatment options for urogenital dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2016;18(10):45.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Xiao-jing Gu
    • 1
  • Bei Cao
    • 1
  • Hui-fang Shang
    • 1
  1. 1.Department of NeurologyWest China Hospital, Sichuan UniversityChengduChina

Personalised recommendations